245 related articles for article (PubMed ID: 35661797)
1. Colon-targeted oral nanoparticles based on ROS-scavenging hydroxyethyl starch-curcumin conjugates for efficient inflammatory bowel disease therapy.
Xu C; Chen S; Chen C; Ming Y; Du J; Mu J; Luo F; Huang D; Wang N; Lin Z; Weng Z
Int J Pharm; 2022 Jul; 623():121884. PubMed ID: 35661797
[TBL] [Abstract][Full Text] [Related]
2. Colon-targeted hydroxyethyl starch-curcumin microspheres with high loading capacity ameliorate ulcerative colitis via alleviating oxidative stress, regulating inflammation, and modulating gut microbiota.
Huang D; Wang Y; Xu C; Zou M; Ming Y; Luo F; Xu Z; Miao Y; Wang N; Lin Z; Weng Z
Int J Biol Macromol; 2024 May; 266(Pt 1):131107. PubMed ID: 38527677
[TBL] [Abstract][Full Text] [Related]
3. Colon-Targeted Oral Delivery of Hydroxyethyl Starch-Curcumin Microcapsules Loaded with Multiple Drugs Alleviates DSS-Induced Ulcerative Colitis in Mice.
Huang D; Zou M; Xu C; Wang Y; Xu Z; Zhang W; Tang S; Weng Z
Macromol Biosci; 2024 Apr; 24(4):e2300465. PubMed ID: 38111343
[TBL] [Abstract][Full Text] [Related]
4. "Dual sensitive supramolecular curcumin nanoparticles" in "advanced yeast particles" mediate macrophage reprogramming, ROS scavenging and inflammation resolution for ulcerative colitis treatment.
Han X; Luo R; Qi S; Wang Y; Dai L; Nie W; Lin M; He H; Ye N; Fu C; You Y; Fu S; Gao F
J Nanobiotechnology; 2023 Sep; 21(1):321. PubMed ID: 37679849
[TBL] [Abstract][Full Text] [Related]
5. Nano-micelles based on hydroxyethyl starch-curcumin conjugates for improved stability, antioxidant and anticancer activity of curcumin.
Chen S; Wu J; Tang Q; Xu C; Huang Y; Huang D; Luo F; Wu Y; Yan F; Weng Z; Wang S
Carbohydr Polym; 2020 Jan; 228():115398. PubMed ID: 31635734
[TBL] [Abstract][Full Text] [Related]
6. pH/ROS dual-sensitive and chondroitin sulfate wrapped poly (β-amino ester)-SA-PAPE copolymer nanoparticles for macrophage-targeted oral therapy for ulcerative colitis.
Xu H; Luo R; Dong L; Pu X; Chen Q; Ye N; Qi S; Han X; Nie W; Fu C; Hu Y; Zhang J; Gao F
Nanomedicine; 2022 Jan; 39():102461. PubMed ID: 34562656
[TBL] [Abstract][Full Text] [Related]
7. Oral Delivery of Nanoparticles Loaded With Ginger Active Compound, 6-Shogaol, Attenuates Ulcerative Colitis and Promotes Wound Healing in a Murine Model of Ulcerative Colitis.
Zhang M; Xu C; Liu D; Han MK; Wang L; Merlin D
J Crohns Colitis; 2018 Jan; 12(2):217-229. PubMed ID: 28961808
[TBL] [Abstract][Full Text] [Related]
8. Oral hydrogel nanoemulsion co-delivery system treats inflammatory bowel disease via anti-inflammatory and promoting intestinal mucosa repair.
Lei F; Zeng F; Yu X; Deng Y; Zhang Z; Xu M; Ding N; Tian J; Li C
J Nanobiotechnology; 2023 Aug; 21(1):275. PubMed ID: 37596598
[TBL] [Abstract][Full Text] [Related]
9. Oral Drug Delivery Systems for Ulcerative Colitis Therapy: A Comparative Study with Microparticles and Nanoparticles.
Ma P; Si X; Chen Q; Ma L; Hou M; Xu Z; Kang Y; Wang J; Xiao B
Curr Cancer Drug Targets; 2019; 19(4):304-311. PubMed ID: 30332962
[TBL] [Abstract][Full Text] [Related]
10. Oral nanotherapeutics with enhanced mucus penetration and ROS-responsive drug release capacities for delivery of curcumin to colitis tissues.
Huang Y; Canup BSB; Gou S; Chen N; Dai F; Xiao B; Li C
J Mater Chem B; 2021 Feb; 9(6):1604-1615. PubMed ID: 33471012
[TBL] [Abstract][Full Text] [Related]
11. Multi-bioresponsive silk fibroin-based nanoparticles with on-demand cytoplasmic drug release capacity for CD44-targeted alleviation of ulcerative colitis.
Gou S; Huang Y; Wan Y; Ma Y; Zhou X; Tong X; Huang J; Kang Y; Pan G; Dai F; Xiao B
Biomaterials; 2019 Aug; 212():39-54. PubMed ID: 31103945
[TBL] [Abstract][Full Text] [Related]
12. Oral delivery of porous starch-loaded bilayer microgels for controlled drug delivery and treatment of ulcerative colitis.
Wen Z; Kang L; Fu H; Zhu S; Ye X; Yang X; Zhang S; Hu J; Li X; Chen L; Hu Y; Yang X
Carbohydr Polym; 2023 Aug; 314():120887. PubMed ID: 37173037
[TBL] [Abstract][Full Text] [Related]
13. Combination Therapy for Ulcerative Colitis: Orally Targeted Nanoparticles Prevent Mucosal Damage and Relieve Inflammation.
Xiao B; Zhang Z; Viennois E; Kang Y; Zhang M; Han MK; Chen J; Merlin D
Theranostics; 2016; 6(12):2250-2266. PubMed ID: 27924161
[TBL] [Abstract][Full Text] [Related]
14. Reactive oxygen species-responsive nanocarrier ameliorates murine colitis by intervening colonic innate and adaptive immune responses.
Yan X; Meng L; Zhang X; Deng Z; Gao B; Zhang Y; Yang M; Ma Y; Zhang Y; Tu K; Zhang M; Xu Q
Mol Ther; 2023 May; 31(5):1383-1401. PubMed ID: 36855303
[TBL] [Abstract][Full Text] [Related]
15. Orally administered covalently-assembled antioxidative peptide nanoparticles for inflammatory bowel disease therapy.
Ma X; Gong H; Liu Y; Liu Y; Ogino K; Xing R; Yan X
J Colloid Interface Sci; 2022 Nov; 626():156-166. PubMed ID: 35780549
[TBL] [Abstract][Full Text] [Related]
16. An efficient enzyme-triggered controlled release system for colon-targeted oral delivery to combat dextran sodium sulfate (DSS)-induced colitis in mice.
Li S; Jin M; Wu Y; Jung S; Li D; He N; Lee MS
Drug Deliv; 2021 Dec; 28(1):1120-1131. PubMed ID: 34121560
[TBL] [Abstract][Full Text] [Related]
17. Enhanced therapeutic efficacy of a novel colon-specific nanosystem loading emodin on DSS-induced experimental colitis.
Wang D; Sun M; Zhang Y; Chen Z; Zang S; Li G; Li G; Clark AR; Huang J; Si L
Phytomedicine; 2020 Nov; 78():153293. PubMed ID: 32777486
[TBL] [Abstract][Full Text] [Related]
18. Inflammation-targeting polyamine nanomedicines for the treatment of ulcerative colitis.
Nishiguchi A; Taguchi T
J Mater Chem B; 2023 May; 11(18):4005-4013. PubMed ID: 37039159
[TBL] [Abstract][Full Text] [Related]
19. pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease.
Beloqui A; Coco R; Memvanga PB; Ucakar B; des Rieux A; Préat V
Int J Pharm; 2014 Oct; 473(1-2):203-12. PubMed ID: 25014369
[TBL] [Abstract][Full Text] [Related]
20. Integration of MyD88 inhibitor into mesoporous cerium oxide nanozymes-based targeted delivery platform for enhancing treatment of ulcerative colitis.
Liu H; Ji M; Bi Y; Xiao P; Zhao J; Gou J; Yin T; He H; Ding H; Tang X; Zhang Y
J Control Release; 2023 Sep; 361():493-509. PubMed ID: 37572964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
